晚期瘤中瘤透淋巴细胞的临床方案II期研究,具有SWI/SNF复合物的改变:TILTS研究

相关实验视频

Updated: Sep 5, 2026

Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model

Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model

Published on: April 13, 2015

Juan Martin-Liberal¹, Elena Garralda², Jesús García-Donas³

¹Catalan Institute of Oncology (ICO), Barcelona, Spain.

Future oncology (London, England)

|August 12, 2024

概括

这项研究研究了使用瘤透性淋巴细胞 (TILs) 进行个性化采用细胞疗法,用于攻击性狂犬病瘤. 该TILTS试验探讨了TILs作为年轻患者这些罕见的,侵略性的癌症的有前途的治疗方法.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
遗传学是一个遗传学.

背景情况:

在SWI/SNF复合组件 (例如,SMARCA4,SMARCB1) 中的突变驱动了侵袭性拉布瘤.
这些罕见的恶性瘤主要影响年轻患者,预后不佳,治疗选择有限.
瘤透淋巴细胞 (TILs) 在这些瘤中丰富,表明瘤抗原的潜在免疫识别.

研究的目的:

介绍第二阶段TILTS研究的临床方案.
为了评估个性化的采用细胞治疗与TILs在患有SWI/SNF突变的狂犬病瘤的患者.
探索TILs作为这些侵袭性癌症的新疗法策略.

主要方法:

这项TILTS研究是一项II期临床试验.
它评估了使用瘤透淋巴细胞 (TILs) 的个性化采用细胞疗法.
该试验的重点是诊断出具有特定攻击性形瘤类型的患者.

主要成果:

本部分详细介绍了TILTS研究的临床方案.
这项研究旨在评估个性化TIL治疗的疗效和安全性.
具体结果将在试验完成后提供.

结论:

用TILs进行个性化采用细胞疗法代表了一个有前途的治疗途径.
这种方法需要进一步研究SWI/SNF突变的侵袭性形瘤.
该TILTS研究协议为评估这种创新的治疗策略提供了一个框架.

关键词:

这就是SMARCA4的标志.在SMARCB1中,在 SWI/SNF 复合体中.它们是.这就是TILs.采用细胞疗法采用细胞疗法免疫疗法免疫疗法拉布多伊德瘤是什么意思

更多相关视频

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia

Published on: December 4, 2018

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.